Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Vaccine
- Pharmaceuticals
- Drug Discovery
- Respiratory
- Disease
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27756
License Grant
The Chinese Licensor will transfer the technology of a pneumococcal vaccine to the Hong Kong Licensee. The Parties will jointly develop the technology. The collaboration term under the technology transfer Agreement is from March 12, 2009 to eight years after the first sale of the vaccine developed under the technology transfer Agreement in Chinese market. On December 14, 2011, an amendment Agreement was signed for the payment of $300 for the transfer of an additional six serotypes and related technology.
License Property
Both parties will work together to develop international markets for the vaccine.
IPSCIO Record ID: 307944
License Grant
Under the Collobaration Agreement, Licensor will make the Ii-Key Peptide vaccine technology available to the Chinese Licensees. The Chinese parties will provide facilities and personnel for the development of the COVID-19 vaccine under Licensor technical guidance. The development will include synthesis, analysis and human trials through Phase III, if warranted, in China. The Chinese parties will have exclusive rights to use and commercialize the COVID-19 technology and products in China.
License Property
The licensed property is Ii-Key Peptide vaccine technology. Ii-Key is a technology that activates the immune response for the treatment of cancer and infectious diseases.
Field of Use
The field of use is to develop a COVID-19 vaccine. The COVID-19 pandemic has opened significant opportunities to resurrect infectious disease vaccine platform Ii-Key Peptide vaccine technology. COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Licensee is an affiliate of the China Technology Exchange, and is enabling the development of the COVID-19 vaccine in China.
IPSCIO Record ID: 375114
License Grant
The Settling Parties agree to resolve all worldwide patent infringement litigation related to the use of defendant’s investigational and licensed (PCV) products, including Vaxneuvance.
License Property
PCV (pneumococcal conjugate vaccine) including Vaxneuvance is an investigational 15-valent pneumococcal conjugate vaccine under review by the EMA for the prevention of invasive disease and pneumonia in adults.
Field of Use
Field of use is for active immunization for the prevention of invasive disease caused by 15 Streptococcus pneumoniae serotypes in adults 18 years of age and older.
Streptococcus pneumoniae is a bacteria that is a major cause of pneumonia. It can spread in persons carrying the bacteria in their upper respiratory tracts by direct person-to-person contact via respiratory droplets.
IPSCIO Record ID: 273254
License Grant
The parties agree that upon the Joint Patent Filing, the 03-111 Technology shall become part of the Patent Rights as defined in the 03-24 License Agreement. Licensor agrees that the inclusion of the 03-111 Technology into the 03-24 License Agreement shall occur without further compensation to University or Licensor, except as specified in this Agreement, and at no additional cost to Licensee. Licensor shall also grant Licensee a non-exclusive, royalty-bearing license to any additional technologies outside of the 03-24 Technology and the 03-111 Technology that are owned or licensed to Licensor (including those acquired by Licensor pursuant to its right of first refusal under the University Subcontract) and that result from work done by University under the University Subcontract for a DNA-based HIV vaccine with protein boost and that are necessary or advantageous to Licensee for the development or commercialization of the HIV Vaccine, with the amount of the royalty to be established in the Definitive Collaborative Agreement and to be negotiated in good faith by the parties. University shall grant Licensee a right of first negotiation to obtain a royalty-bearing license to University exclusive or non-exclusive rights to any additional technology outside of the 03-24 Technology and 03-111 technology that are owned by University and have not been acquired or licensed to Licensee pursuant to its right of first refusal under the University Subcontract and that result from work done under the University Subcontract and that are necessary or advantageous to Licensee for the development or commercialization of the HIV Vaccine. Licensor shall represent that it does not currently own or have any other rights to any other technology that would be infringed by the development or commercialization of the HIV Vaccine.
License Property
The '03-24 Technology – U.S. Patent Application Serial Number 60/430,732 (the '03-24 Patent Filing') with the United States Patent and Trademark Office covering a foundational HIV vaccine technology invention referred to by University as UMMC 03-24.
The '03-111 Technology – U. S. Patent Application Serial Number 60/503,907 (the '03-111 Patent Filing') covering an HIV protein boost technology invention referred to by University and Licensor as UMMC 03-111.
Field of Use
This agreement pertains to HIV vaccine.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
